Discovery of anticoagulant drugs: A historical perspective

Current Drug Discovery Technologies

Volumn 9, Issue 2, 2012, Pages 83-104

  Gémez Outes, Antonio ^a   Suárez Gea, Ma Luisa ^a   Calvo Rojas, Gonzalo ^b   Lecumberri, Ramén ^c   Rocha, Eduardo ^d   Pozo Hernández, Carmen ^a   Terleira Fernández, Ana Isabel ^e   Vargas Castrillén, Emilio ^e  

^a Parque Empresarial Las Mercedes   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Anticoagulants; Heparin; Hirudin; History; Warfarin

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ARDEPARIN; ARGATROBAN; BEMIPARIN; CERTOPARIN; DABIGATRAN; DABIGATRAN ETEXILATE; DALTEPARIN; DESULFATOHIRUDIN; DICOUMAROL; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; INOGATRAN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; PHENPROCOUMON; PHYTOMENADIONE; PROTAMINE; RD 11885; RECOMBINANT HIRUDIN; REVIPARIN; RIVAROXABAN; SANORG 32701; TINZAPARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ARTERY OCCLUSION; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HUMAN; HYPOPROTHROMBINEMIA; LUNG EMBOLISM; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84860540835     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/1570163811209020083     Document Type: Review

References (284)

1. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451: 914-8.
2. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008; 28: 370-2.
3. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-64. (Pubitemid 47555066)
4. Roger VL, Go AS, Lloyd-Jones DM, et al., on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2011 Update: A Report From the American Heart Association. Circulation 2011; 123: e18-e209
5. Mueller RL, Scheidt S. History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation 1994; 89: 432-49. (Pubitemid 24979843)
6. Schlueter PJ, Peterson RT. Systematizing serendipity for cardiovascular drug discovery. Circulation 2009; 120: 255-63.
7. Ban TA. The role of serendipity in drug discovery. Dialogues Clin Neurosci 2006; 8: 335-44. (Pubitemid 44682750)
8. Samama MM. Discovery of drugs in haemostasis and thrombosis by serendipity. Pathophysiol Haemos Thromb 2009/2010; 37(Suppl.1): P1.
9. Liu H, Zhang Z, Linhardt RJ. Lessons learned from the contamination of heparin. Nat Prod Rep 2009; 26: 313-21.
10. Villax G. Business of Counterfeit Heparin and its implications. Presentation at the 3rd EFCG Pharma Business Conference, Lisbon, Portugal, 29-30th May, 2008. Available from URL: http://efcg.cefic.org/isoFILES/ publications/items/DOWNLOAD-1 81.pdf [Accessed 2010 Dec 27].
11. Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Rocha E, Pozo- Hernández C, Vargas-Castrillón E. New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis 2011; 5: 33-59
12. Lam CR. The strange story of Jay McLean, the discoverer of heparin. Henry Ford Hosp Med J 1985; 33: 18-23. (Pubitemid 15063487)
13. Couch NP. About heparin, or ... whatever happened to jay McLean? J Vasc Surg 1989; 10: 1-8. (Pubitemid 19187551)
14. Baird RJ. Presidential address: "Give us the tools . . ." the story of heparin-as told by sketches from the lives of William Henry Howell, Jay McLean, Charles Best, and Gordon Murray. J Vasc Surg 1990; 11: 4-18. (Pubitemid 20038305)
15. Marcum JA. The origin of the dispute over the discovery of heparin. J Hist Med Allied Sci 2000; 55: 37-66.
16. Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008; 141: 757-63. (Pubitemid 351724858)
17. Copeland CE, Six CK. A tale of two anticoagulants: warfarin and heparin. J Surg Educ 2009; 66: 176-81.
18. McLean J. The thromboplastic action of cephalin. Am J Physiol 1916; 41: 250-7.
19. McLean J. The discovery of heparin. Circulation 1959; 19: 75-8.
20. Best CH. Preparation of heparin and its use in the first clinical cases. Circulation 1959; 19: 79-86.
21. Howell WH, Holt E. Two new factors in blood coagulation - heparin and pro-antithrombin. Am J Physiol 1918; 47: 328-41.
22. Mason MC. A note on the use of heparin in blood transfusion. J Lab Clin Med 1924; 10: 203-6.
23. Howell WH, MacDonald CH. Note on the effect of repeated intravascular injections of heparin. Bull Johns Hopkins Hosp 1930; 46: 365-8.
24. Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med 1922; 7: 251-66.
25. Rutty CJ. Miracle blood lubricant: Connaught and the story of heparin, 1928-1937. Available from URL: http://www. healthheritageresearch.com/Heparin- Conntact9608.html [Accessed 2010 Dec 27].
26. Charles AF, Scott DA. Studies on heparin: I. The preparation of heparin. J Biol Chem 1933; 102: 425-9.
27. Scott DA, Charles AF. Studies on heparin: III The purification of heparin. J Biol Chem 1933; 102: 437-48.
28. Charles AF, Scott DA. Studies on heparin: Observations on the chemistry of heparin. Biochem J 1936; 30: 1927-33.
29. Schmitz A, Fischer A. Uber die chemisches nature des heparins. II. Die reindarstellung des heparins. Seit Physiol Chem 1933; 216: 264-9.
30. Shampo MA, Kyle RA. J. Erik Jorpes - pioneer in the identification and clinical applications of heparin. Mayo Clin Proc 1997; 72: 1056.
31. Mutt V, Blombäck M. Erik Jorpes - a pragmatic physiological chemist. Compr Biochem 2000; 41: 363-89.
32. Jorpes JE. The chemistry of heparin. Biochem J 1935; 29: 1817-30.
33. Jorpes JE. Heparin: A mucopolysaccharide and an active antithrombotic drug. Circulation 1959; 19: 87-91.
34. Murray G, Delorme E, Thomas N. Development of an artificial kidney. Arch Surg 1947; 55: 505-22.
35. McKellar S. Gordon Murray and the artificial kidney in Canada. Nephrol Dial Transplant 1999; 14: 2766-70. (Pubitemid 32208403)
36. Murray GDW, Best CH. The use of heparin in thrombosis. Ann Surg 1938; 108: 163-77.
37. Murray GDW, Jaques LB, Perrett TS, Best CH. Heparin and vascular occlusion. Can Med Assoc J 1936; 35: 621-2.
38. Murray GDW, Jaques LB, Perrett TS, Best CH. Heparin and the thrombosis of veins following injury. Surgery 1937; 2: 163-87.
39. Hedenius P, Wilander O. The influence of intravenous injections of heparin in man on the time of coagulation. Acta Med Scand 1936; 88: 443-9.
40. Crafoord C. Preliminary report on post-operative treatment with heparin as a preventive of thrombosis. Acta Chir Scand 1937; 79: 407-26.
41. Böttiger LE. The heparin story. In search of the early history of heparin. Acta Med Scand 1987; 222: 195-200.
42. Liquaemin® (heparin sodium) label information. Available from URL: http://www.accessdata.fda.gov [Accessed 2010 Dec 27].
43. Prandoni A, Wright I. The Anti-Coagulants: Heparin and the Dicoumarin- 3, 3' Methylene-Bis-(4-Hydroxycoumarin). Bull N Y Acad Med 1942; 18: 433-58.
44. Aggeler PM. Heparin and Dicumarol-Anticoagulants: Their prophylactic and therapeutic uses. Cal West Med 1946; 64: 71-7.
45. Taylor EM, Moloney PJ. Methods of producing heparin. U.S. Patent Number: 2,587,924; Filed: May 27, 1948; Serial N: 29,670; Available from URL: http://www.freepatentsonline.com/2587924. pdf [Accessed 2010 Dec 30]
46. Fischer A. Die Bindung von Heparin an Eiweiss. Biochem Z 1935; 278: 133.
47. Chargaff E, Olson KB. Studies on the chemistry of blood coagulation. VI. Studies on action of heparin and other anticoagulants. The influence of protamine on the anticoagulant effect in vivo. J Biol Chem 1937; 122: 153-67.
48. Jorpes E, Edman P, Thaning T. Neutralisation of action of heparin by protamine. Lancet 1939; 2: 975-6.
49. Bangham DR, Mussett MV. The second International Standard for Heparin. Bull Wld Hlth Org 1959; 20: 1201-8.
50. Kolff WJ, Berk HT, ter Welle M, van der LEY AJ, van Dijk EC, van Noordwijk J. The artificial kidney: a dialyser with a great area. 1944. J Am Soc Nephrol 1997; 8: 1959-65. (Pubitemid 128756105)
51. Stammers AH. Historical aspects of cardiopulmonary bypass: from antiquity to acceptance. J Cardiothorac Vasc Anesth 1997; 11: 266-74. (Pubitemid 27214895)
52. Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. J Lab Clin Med 1953; 41: 637-47.
53. Margolis J. The kaolin clotting time. A rapid one-stage method for diagnosis of coagulation defects. J Clin Pathol 1958; 11: 406-9.
54. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961; 36: 212-9.
55. Messmore HL, Wehrmacher WH, Coyne E, Fareed J. Heparin to pentasaccharide and beyond: the end is not in sight. Semin Thromb Hemost 2004; 30(Suppl.1): 81-8. (Pubitemid 38453586)
56. Ulin AW, Gollub S. Posthumous award commemorating the discovery of heparin. N Engl J Med 1964; 270: 466.
57. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI; American College of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 141S- 159S. (Pubitemid 351892966)
58. Iverius PH. Coupling of glycosaminoglycans to agarose beads (sepharose 4B). Biochem J 1971; 124: 677-83.
59. Abildgaard U. Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest 1968; 21: 89-91.
60. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-505.
61. Rosenberg RD, Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci USA 1979; 76: 1218-22. (Pubitemid 9135185)
62. Lindahl U, Bäckström G, Höök M, Thunberg L, Fransson LA, Linker A. Structure of the antithrombin-binding site in heparin. Proc Natl Acad Sci USA 1979; 76: 3198-202.
63. Johnson EA, Kirkwood TBL, Stirling Y, et al. Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost 1976; 35: 586-91.
64. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GE. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-3.
65. Choay J, Lormeau JC, Petitou M, et al. Anti-Xa active heparin oligosaccharides. Thromb Res 1980; 18: 573-8. (Pubitemid 10090431)
66. Lormeau JC, Choay J, Petitou M. Process for making oligosaccharides having anti-Xa activity and the resulting oligosaccharides. U.S. Patent Number: 4,401,758; Filed: October 6, 1980. Available from URL: http://www. freepatentsonline.com/4401758.pdf [Accessed 2010 Dec 31].
67. Guyotjeannin MC. Jean Choay (1923-1993). Ann Pharm Fr 1993; 51: 167-9.
68. Hirsh J, Levine M. Low molecular weight heparin. Blood 1992; 79: 1-17.
69. Hirsh J, Weitz JI. New antithrombotic agents. Lancet 1999; 353: 1431-6. (Pubitemid 29192427)
70. Warkentin T, Levine M, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
71. Shaughnessy S, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from the fetal rat calvaria. Blood 1995; 86: 1368-73
72. Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ; American College of Chest Physicians. Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 71S-109S. (Pubitemid 351892961)
73. Voelker R. FDA approves generic enoxaparin. JAMA 2010; 304: 844.
74. Demir M, Iqbal O, Dietrich CP, et al. Anticoagulant and antiprotease effects of a novel heparinlike compound from shrimp (Penaeus brasiliensis) and its neutralization by heparinase I. Clin Appl Thromb Hemost 2001; 7: 44-52. (Pubitemid 32112602)
75. Guerrini M, Shriver Z, Bisio A, et al. The tainted heparin story: an update. Thromb Haemost 2009; 102: 907-11.
76. Lindahl U, Bäckström G, Thunberg L, Leder IG. Evidence for a 3- O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci USA 1980; 77: 6551-5. (Pubitemid 11219166)
77. Casu B, Oreste P, Torri G, et al. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear- magnetic-resonance studies. Biochem J 1981; 197: 599-609. (Pubitemid 12232759)
78. Thunberg L, Bäckström G, Lindahl U. Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res 1982; 100: 393-410.
79. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure- activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-9. (Pubitemid 14242772)
80. Petitou M, van Boeckel CAA. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew Chem Int Ed 2004; 43: 3118-33. (Pubitemid 39257600)
81. Walenga JM, Fareed J, Jeske WP, Frapaise FX, Bick RL, Samama MM. Development of a Synthetic heparin pentasaccharide: Fondaparinux. Turk J Haematol 2002; 19: 137-50. (Pubitemid 35229920)
82. Sinay P, Jacquinet JC, Petitou M, et al. Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III. Carbohydr Res 1984; 132: C5-C9.
83. van Boeckel CAA, Beetz T, Vos JN, et al. Synthesis of a pentasaccharide corresponding to the antithrombin III-binding fragment of heparin. J Carbohydr Chem 1985; 4: 293-321. (Pubitemid 16219104)
84. Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of Sanorg 32701- Comparison with the ''syntheric pentasaccharide'' (SR 90107/ORG 31540) and standard heparin. Circ Res 1996; 79: 590-600. (Pubitemid 26276919)
85. Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91: 4197-205. (Pubitemid 28261983)
86. van Amsterdam RGM, Vogel GMT, Visser A, Kop WJ, Buiting MT, Meuleman DG. Synthetic analogs of the antithrombin IIIbinding pentasaccharide sequence of heparin -Prediction of the in vivo residence times. Arterioscler Thromb Vasc Biol 1995; 15: 495-503.
87. Paty I, Trellu M, Destors JM, Cortez P, Boëlle E, Sanderink G. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010; 8: 722-9.
88. Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 2009; 102: 811-5.
89. Gómez-Outes A, Lecumberri R, Pozo C, Rocha E. New anticoagulants: focus on venous thromboembolism. Curr Vasc Pharmacol 2009; 7: 309-29.
90. Petitou M, Nancy-Portebois V, Dubreucq G, et al. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb Haemost 2009; 102: 804-10.
91. Petitou M, Duchaussoy P, Lederman I, et al. Synthesis of heparin fragments: a methyl alpha-pentaoside with high affinity for antithrombin III. Carbohydr Res 1987; 167: 67-75.
92. Codée JDC, Overkleeft HS, Van der Marel GA, Van Boeckel CAA. The synthesis of well-defined heparin and heparan sulfate fragments. Drug Discov Today 2004; 1: 317-26. (Pubitemid 40197582)
93. Arixtra® (fondaparinux sodium) label information. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index. cfm [Accessed 2011 Mar 21].
94. Arixtra® (fondaparinux sodium) summary of product characteristics. Available from URL: http://www.ema.europa.eu [Accessed 2011 Mar 21].
95. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized doubleblind studies. Arch Intern Med 2002; 162: 1833-40.
96. Link KP. The discovery of dicumarol and its sequels. Circulation 1959; 19: 97-107.
97. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 160S-198S. (Pubitemid 351892967)
98. Navarro JL, César JM, Fernández MA, Fontcuberta J, Reverter JC, Gol-Freixa J. Morbilidad y mortalidad en pacientes con tratamiento anticoagulante oral. Rev Esp Cardiol 2007; 60: 1226-32. (Pubitemid 350294321)
99. National Institute for Clinical Excellence (NICE). Anticoagulation commisioning guide. NICE Clinical Guideline 36. 2007; Available from URL: http://www.nice.org.uk [Accessed 2010 Dec 30]
100. Virjo I, Mäkelä K, Aho J, et al. Who receives anticoagulant treatment with warfarin and why? A population-based study in Finland. Scand J Prim Health Care 2010; 28: 237-41.
101. World population prospects. The 2010 Population Revision Database; Available from URL: http://esa.un.org/unpd/wpp/ [Accessed 2011 Jul 23].
102. Rogers EM. Diffusion of innovations. 5th edition; ed. The Free Press, New York, 2003.
103. Griminger P. Vitamin K antagonists: the first 50 years. J Nutr 1987; 117: 1325-9.
104. Kresge N, Simoni RD, Hill RL. Hemorrhagic sweet clover disease, Dicumarol and warfarin: the work of Karl Paul Link. J Biol Chem 2005; 280: e5.
105. Last JA. The missing link: The story of Karl Paul Link. Toxicol Sci 2002; 66: 4-6. (Pubitemid 34202023)
106. Schofield FW. A brief account of a disease in cattle simulating hemorrhagic septicemia due to feeding sweet clover. Can Vet Record 1922; 3: 74-78.
107. Schofield FW. Damaged sweet clover: the cause of a new disease in cattle simulating hemorrhagic septicaemia and blackleg. Am Vet Med Assoc 1923/24; 64: 553-75.
108. Roderick LM, Schalk F. Studies on sweet clover disease. North Dakota Agric Exp Stat Bull 1931; 250: 1-56.
109. Quick AJ. The prothrombin time in haemophilia and in obstructive jaundice. J Biol Chem 1935; 109; 73-4.
110. Stahmann MA, Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent. J Biol Chem 1941; 138: 513-27.
111. Campbell HA, Link KP. Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. J Biol Chem 1941; 138: 21-33.
112. Overman RS, Stahmann MA, Huebner CF, et al. Studies on the hemorrhagic sweet clover disease. XIII. Anticoagulant activity and structure in the 4-hydroxycoumarin group. J Biol Chem 1944; 153: 5-24.
113. Link KP. The anticoagulant from spoiled sweet clover hay. Harvey Lect 1943; 34: 162-216.
114. Butt HR, Allen EV, Bollman JL. A preparation from spoiled sweet clover [3, 31-methylene-bis-(4-hydroxycoumarin)] which prolongs coagulation and prothrombin time of blood: preliminary report of experimental and clinical studies. Proc Staff Meet Mayo Clin 1941; 16: 388-95.
115. Shapiro S. Warfarin sodium derivative (Coumadin sodium): intravenous hypoprothrombinemia-inducing agent. Angiology 1953; 4: 380-90.
116. Clatanoff DV, Triggs PO, Meyer OO. Clinical experience with coumarin anticoagulants warfarin and warfarin sodium. Arch Int Med 1954; 94: 213-20.
117. Coumadin® (warfarin sodium) label information. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index. cfm [Accessed 2011 Mar 21].
118. Pollock BE. Clinical experience with warfarin (Coumadin) sodium, a new anticoagulant. JAMA 1955; 159: 1094-7.
119. Jürgens R. Experimentelle Untersuchungen über das Antikoagulans Marcoumar (3-(1-Phenyl-propyl)-4-oxy-cumarin) und seinen Antagonisten Konakion (synthetisches Vitamin K1). Schweiz Med Wochenschr 1953; 83: 471-5.
120. Koller F, Jakob H. Uber ein neues, hochaktives Antikoagulans mit protrahierter Wirkung (Marcoumar). Schweiz Med Wochenschr 1953; 83: 476-9.
121. Stoll WG, Litvan F. Der Einfluss der substitution in 4- oxycumarinderivaten auf die gerinnungsvalenz des blutes. In: Thrombosis and Embolism, I. International Conference, Basel, 1954; eds. Basel, Benno Schwabe & Co., 1955; pages: 244-50.
122. Stoll W, Litvan F. 3-substituted 4-hydroxycoumarins and process for their production. U.S. Patent 2,648,682, 1953; assigned to J.R. Geigy A.G., Basel, Switzerland. Available at: http://www. freepatentsonline.com/2648682.pdf [Accessed on December 31, 2010]
123. Montigel C, Pulver R. [Animal experimental studies with a new highly potent 4-hydroxycoumarin derivative with short action: sintrom (G 23350)]. Schweiz Med Wochenschr 1955; 85: 586-90.
124. Moeschlin S, Schorno H. [Clinical experience with a new 4- hydroxycoumarin derivative: sintrom (Geigy 23350)]. Schweiz Med Wochenschr 1955; 85: 590-2.
125. Stenflo J, Fernlund P, Egan W, Roepstorff P. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 1974; 71: 2730-3.
126. Nelsestuen GL, Zytkovicz TH, Howard JB. The mode of action of vitamin K: identification of gamma-carboxyglutamic acid as a component of prothrombin. J Biol Chem 1974; 249: 6347-50.
127. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 1978; 17: 1371-7. (Pubitemid 8330368)
128. Kresge N, Simoni RD, Hill RL. The function of vitamin K: the work of John W. Suttie. J Biol Chem 2008; 283: e9.
129. Quick AJ. The development and use of the prothrombin tests. Circulation 1959; 19: 92-6.
130. Owren PA. The coagulation of blood: investigations on a new clotting factor. Acta Med Scand 1947; 194: 521-49.
131. Stormorken H. The discovery of factor V: a tricky clotting factor. J Thromb Haemost 2003; 1: 206-13.
132. Owren PA. A quantitative one-stage method for the assay of prothrombin. Scand J Clin Lab Invest 1949; 1: 81-3.
133. Owren PA. Thrombotest. A new method for controlling anticoagulant therapy. Lancet 1959; 2: 754-8.
134. Dam H. The antihemorrhagic vitamin of the chick: occurrence and chemical nature. Nature 1935; 135: 652-3.
135. Almquist HJ, Klose AA. Synthetic and natural antihemorrhagic compounds. J Am Chem Soc 1939; 61: 2557-8.
136. MacCorquodale DW, Binkley SB, Thayer SA, Doisy EA. On the constitution of Vitamin K1. 1939. J Am Chem Soc 1939; 61: 1928-9.
137. Fieser LR, Campbell WP, Fry EM, Gates MD Jr. Synthesis of 2- methyl-3-phytiyl-1,4-naphthoquinone. J Am Chem Soc 1939; 61: 2559-61.
138. Karrer P, Geiger A, Rüegger A, Salomon H. Über Nor-α- phyllochinon (Nor-Vitamin-K1) und ähnliche Verbindungen (Vorläufige Mitteilung). Helv Chim Acta 1939; 22: 1513-6.
139. Almquist HJ. The early story of vitamin K. Am J Clin Nutr 1975; 28: 656-9.
140. Jukes TH. Herman James Almquist (1903- ): biographical sketch. J Nutr 1987; 117: 409-15.
141. Shapiro S, Redish MH, Campbell HA. Prothrombin Studies. III. Effect of vitamin K upon hypopothrombinemia induced by dicumarol in man. Proc Soc Exp Biol Med 1943; 52: 12-5.
142. Miller R, Harvey WP, Finch CA. Antagonism of dicumarol by vitamin K preparations. New Eng J Med 1950; 242: 211-5.
143. Toohey M. Antagonism of anticoagulants dicoumarol, tromexan, and phenylindandione by vitamin K. Br Med J 1952; 2: 687-90.
144. Gamble JR, Dennis EW, Coon WW, et al. Clinical comparison of Vitamin K1 and water-soluble vitamin K. Arch Intern Med 1955; 95: 52-8.
145. Udall JA. Don't use the wrong vitamin K. Calif Med 1970; 112: 65-7.
146. Goldsack NR, Chambers RC, Dabbagh K, Laurent GJ. Thrombin. Int J Biochem Cell Biol 1998; 30: 641-6.
147. Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Haemost 2006; 32: 3-15.
148. Kimball SD. Challenges in the development of orally bioavailable thrombin active site inhibitors. Blood Coagul Fibrinolysis 1995; 6: 511-9.
149. Ledizet M, Harrison LM, Koskia RA, Cappello M. Discovery and pre-clinical development of antithrombotics from hematophagous invertebrates. Curr Med Chem Cardiovasc Hematol Agents 2005; 3: 1-10. (Pubitemid 40057726)
150. Coh CY, Kini RM. Molecular Diversity of anticoagulants from Haematophagous animals. Thromb Haemost 2009; 102: 437-53.
151. Salzet, M. Anticoagulants and inhibitors of platelet aggregation derived from leeches. FEBS Lett 2001; 492: 187-92. (Pubitemid 32217826)
152. Nowak G, Schrör K. Hirudin - the long and stony way from an anticoagulant peptide in the saliva of medicinal leech to a recombinant drug and beyond. A historical piece. Thromb Haemost 2007; 98: 116-9. (Pubitemid 47078781)
153. Whitaker IS, Rao J, Izadi D, Butler PE. Historical Article: Hirudo medicinalis: ancient origins of, and trends in the use of medicinal leeches throughout history. Br J Oral and Maxillofacial Surg 2004; 42: 133-7. (Pubitemid 38401331)
154. Haycraft JB. On the action of a secretion obtained from the medicinal leech on coagulation of the blood. Proc R Soc Lond 1884; 36: 478-87.
155. Schultze E. Über die Verwendung von Blutegelextrakt bei der Transfusion des Blutes. Dissertation. University of Greifswald, 1891.
156. Blobel P. Versuche über Transfusion mit dem vom Blutegel gesogenen Blute und über die Verwendung frisch bereiteten Egeldecoctes zur Transfusion. Dissertation, University of Greifswald, 1892.
157. Sahli H. Über den Einfluβ intravenös injizierten Blutegelextraktes auf die Thrombenbildung. Zentralbl F Inn Med 1894; 22: 497-501.
158. Waldmann-Brun S. Carl Jacobj: Leben und Werk. Dissertation. University of Tübingen, 2008; Available from URL: http://tobiaslib. uni-tuebingen.de [Accessed on 2010 Dec 30]
159. Jacobj C. Verfahren zur Darstellung des die Blutgerinnung aufhebenden Bestandtheiles des Blutegels. D.R.P., 1902; Patent Number; 136103, Klasse 30h/204.
160. Jacobj C. Über den die Blutgerinnung aufhebenden, wirksamen Bestandteil des Blutegels. Dtsch med Wschr 1902; 32: 250-1.
161. Franz F. Ueber den die Blutgerinnung aufhebenden Bestandteil des medizineschen Blutegels. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1903; 49: 342-66.
162. JacobJ C. Über hirudin. Dtsch Med Wschr 1904; 30: 1786-7.
163. Morawitz P. Die Chemie der Blutgerinnung. Ergebn Physiol 1905; 4: 307-32.
164. Engelmann F, Stade C. Über die Bedeutung des Blutegelextraktes für die Therapie der Eklampsie. Münch Med Wochenschr 1909; 43: 2203-7.
165. Abel JJ, Rowntree LC, Turner BB. On the removal of diffusible substances from the circulating blood of living animals by dialysis. J Pharmacol Exp Ther 1913-1914; 5: 275-316.
166. Haas G. Versuche der Blutauswaschung am Lebenden mit Hilfe der Dialyse. Klin Wschr 1925; 4: 13-4.
167. Termier J. Traitement abortif des phlébites chirurgicales avec lever précoce. Congres francais de Chirurgie. Proces-verbaux et Memoires. Press Med 1922; 31: 949.
168. Mahorner HR, Ochsner A. The use of leeches in the treatment of phlebitis and the prevention of pulmonary embolism. Ann Surg 1933; 98: 408-21.
169. Markwardt F. Untersuchungen über Hirudin. Naturwissenschaften 1955; 52: 537.
170. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1-23. (Pubitemid 24257425)
171. Markwardt F. Die Isolierung und chemische Charakterisierung des Hirudins. Hoppe Seylers Z Physiol Chem 1957; 308: 147-56.
172. Petersen TE, Roberts HR, Sottrup-Jensen L, Magnusson S. Primary structure of hirudin, a thrombin-specific inhibitor. In: Protides of the Biological Fluids, Vol. 23; Peeters H (Ed.). Pergamon Press, Oxford 1976; Pages: 145-9.
173. Dodt J, Seemüller U, Maschler R, Fritz H. The complete covalent structure of hirudin. Biol Chem Hoppe-Seyler 1985; 366: 379-85.
174. Fields WS. The history of leeching and hirudin. Haemostasis 1991; 21(Suppl 1): 3-10.
175. Harvey RP, Degryse E, Stefani L, et al. Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis. Proc Natl Acad Sci USA 1986; 83: 1084-8. (Pubitemid 16086416)
176. Bergmann C, Dodt J, Kohler S, Fink E, Gassen HG. Chemical synthesis and expression of a gene coding for hirudin, the thrombin- specific inhibitor from the leech Hirudo medicinalis. Biol Chem Hoppe Seyler 1986; 367: 731-40.
177. Fortkamp E, Rieger M, Heisterberg-Moutses G. Cloning and expression in Escherichia coli of a synthetic DNA for hirudin, the blood coagulation inhibitor in the leech. DNA 1986; 5: 511-17. (Pubitemid 17231747)
178. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989; 8: 3467-75. (Pubitemid 19273577)
179. Grütter MG, Priestle JP, Rahuel J, et al. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition. EMBO J 1990; 9: 2361-5.
180. Baetz BE, Spinler SA. Dabigatran etexilate: An oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy. 2008; 28: 1354-73.
181. Banner DW, Hadvary P. Crystallographic analysis at 3.0 A resolution of the binding to human thrombin of four active site-directed inhibitors. J Biol Chem 1991; 266: 20085-93. (Pubitemid 21908430)
182. Brandstetter H, Turk D, Hoeffken HW, et al. Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4- TAPAP and MQPA. J Mol Biol 1992; 226: 1085-99.
183. Kikelj D. Peptidomimetic thrombin inhibitors. Pathophysiol Haemost Thromb 2003/2004; 33: 487-91. (Pubitemid 40278729)
184. Hruby VJ, Balse PM. Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. Curr Med Chem 2000; 7: 945-70.
185. Okamoto S, Hijikata A, Kikumoto R, et al. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981; 101: 440-6.
186. Ikoma H. Development of argatroban as an anticoagulant and antithrombin agent in Japan. Pathophysiol Haemost Thromb 2002; 32(suppl 3): 23-8. (Pubitemid 37449300)
187. Ikeda Y, Wanaka K, Okamoto U. Okamoto's strategy to develop argatroban: An innovative concept for the future. Semin Thromb Hemost 2008; 34: 7-11.
188. Okamoto S. Strategies for creating new medicines. Kobe: Kobe Research Project on Thrombosis and Hemostasis; 2003.
189. Okamoto S, Hijikata A, Kinjo K, et al. A novel series of synthetic thrombin-inhibitors having extremely potent and highly selective action. Kobe J Med Sci 1975; 21: 43-51.
190. Okamoto S, Kinjo K, Hijikata A, et al. Thrombin inhibitors. 1. Ester derivatives of N alpha-(arylsulfonyl)-L-arginine. J Med Chem 1980; 23: 827-30. (Pubitemid 10091523)
191. Astbury WT. Molecular biology or ultrastructural biology? Nature 1961; 190: 1124.
192. Argatroban® (argatroban) label information. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Accessed 2011 Mar 21].
193. Römisch J, Diehl KH, Hoffmann D, et al. Comparison of in vitro and in vivo properties of rhirudin (HBW 023) and a synthetic analogous peptide. Haemostasis 1993; 23: 249-58. (Pubitemid 24051058)
194. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 2001; 10: 1479-84. (Pubitemid 32220644)
195. Refludan® (lepirudin) summary of product characteristics. Available from URL: http://www.ema.europa.eu [Accessed 2011 Mar 21].
196. Refludan® (lepirudin) label information. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Accessed 2011 Mar 21].
197. Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73-80. (Pubitemid 29035960)
198. Greinacher A, Janssens U, Berg G, et al.; Heparin-Associated Thrombocytopenia Study (HAT) investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin- induced thrombocytopenia. Circulation 1999; 100: 587-93.
199. Talbot MD, Ambler J, Butler KD, et al. Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemost 1989; 61: 77-80. (Pubitemid 19092672)
200. Talbot M. Biology of recombinant hirudin (CGP 39393): a new prospect in
201. Iprivask® (desirudin) label information. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Accessed 2011 Mar 21].
202. Revasc® (desirudin) summary of product characteristics. Available from URL: http://www.ema.europa.eu [Accessed 2011 Mar 21].
203. Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandra KL. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 1989; 264: 8692-8. (Pubitemid 19151588)
204. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-101. (Pubitemid 20241158)
205. Shammas NW. Bivalirudin: pharmacology and clinical applications. Cardiovasc Drug Rev 2005; 23: 345-60. (Pubitemid 43853856)
206. Angiomax® (bivalirudin) label information. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Accessed 2011 Mar 21].
207. Angiox® (bivalirudin) summary of product characteristics. Available from URL: http://www.ema.europa.eu [Accessed 2011 Mar 21].
208. Gustafsson D, Bylund R, Antonsson T, et al. A new oral anticoagulant: the 50-year challenge. Nat Rev Drug Discov 2004; 3: 649-59. (Pubitemid 39173506)
209. Gustafsson D, Elg M, Lenfors S, Börjesson I, Teger-Nilsson AC. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coagul Fibrinolysis 1996; 7: 69-79. (Pubitemid 26106172)
210. The Thrombin Inhibition in Myocardial Ischaemia (TRIM) study group. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Eur Heart J 1997; 18: 1416-25.
211. Cohen AT, Hirst C, Sherrill B, Holmes P, Fidan D. Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery. Br J Surg 2005; 92: 1335-44. (Pubitemid 41546629)
212. Francis CW, Berkowitz SD, Comp PC, et al.; EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349: 1703-12. (Pubitemid 37315007)
213. Colwell CW Jr, Berkowitz SD, Lieberman JR, et al.; EXULT B Study Group. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 2005; 87: 2169-77. (Pubitemid 41407539)
214. Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-8. (Pubitemid 37468318)
215. Albers GW, Diener HC, Frison L, et al.; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690-8.
216. Schulman S, Wahlander K, Lundström T, Clason SB, Eriksson H; THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713-21. (Pubitemid 37315008)
217. Boudes PF. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemp Clin Trials 2006; 27: 432-40. (Pubitemid 44189275)
218. Agnelli G, Eriksson BI, Cohen AT, et al. EXTEND Study Group. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res 2009; 123: 488-97.
219. Deinum J, Mattsson C, Inghardt T, Elg M. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost 2009; 101: 1051-9.
220. Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009; 30: 2897-907.
221. Lip GY, Rasmussen LH, Olsson SB, et al., on behalf of the Steering Committee. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: A Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. Thromb Res 2011; 127: 91-9.
222. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45: 1757-66. (Pubitemid 34415371)
223. Mungall D. BIBR-1048 Boehringer Ingelheim. Curr Opin Investig Drugs 2002; 3: 905-7. (Pubitemid 36266808)
224. Pradaxa® (dabigatran etexilate) summary of product characteristics. Available from URL: http://www.ema.europa.eu [Accessed 2011 Mar 21].
225. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101: 77-85.
226. Pradaxa® (dabigatran etexilate) label information. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index. cfm [Accessed 2011 Mar 21].
227. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
228. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007; 5(Suppl.1): 60-4. (Pubitemid 46958817)
229. Padmanabhan K, Padmanabhan KP, Tulinsky A, et al. Structure of human des(1-45) factor Xa at 2.2 A resolution. J Mol Biol 1993; 232: 947-66. (Pubitemid 23256984)
230. Vlasuk GP, Ramjit D, Fujita T, et al. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991; 65: 257-62.
231. Tuszynski GP, Gasic TB, Gasic GJ. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation. J Biol Chem 1987; 262: 9718-23. (Pubitemid 17102618)
232. Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-6.
233. Pinto DJ, Smallheer JM, Cheney DL, Knabb RM, Wexler RR. Factor Xa inhibitors: next-generation antithrombotic agents. J Med Chem 2010; 53: 6243-74.
234. Pauls HW, Ewing WR. The design of competitive, small molecule inhibitors of coagulation factor Xa. Curr Top Med Chem 2001; 1: 83-100.
235. Saiah E, Soares C. Small molecule coagulation cascade inhibitors in the clinic. Curr Top Med Chem 2005; 5: 1677-95.
236. Masic LP. Arginine mimetic structures in biologically active antagonists and inhibitors. Curr Med Chem 2006; 13: 3627-48. (Pubitemid 44882612)
237. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov 2011; 10: 61-75.
238. Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994; 71: 314-9. (Pubitemid 24083741)
239. Kaiser B. DX-9065a, a direct inhibitor of factor Xa. Cardiovasc Drug Rev 2003; 21: 91-104. (Pubitemid 36935488)
240. Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 1995; 92: 485-91.
241. Morishima Y, Shibano T. [Research and development strategy of antithrombotic agents: pharmacology of the oral factor Xa-inhibitor edoxaban]. Nippon Yakurigaku Zasshi 2010; 136: 83-7.
242. de Candia M, Lopopolo G, Altomare C. Novel factor Xa inhibitors: a patent review. Expert Opin Ther Patents 2009; 19: 1-46.
243. Straub A, Roehrig S, Hillisch A. Entering the era of non-basic p1 site groups: discovery of Xarelto (Rivaroxaban). Curr Top Med Chem 2010; 10: 257-69.
244. Xarelto® (rivaroxaban) summary of product characteristics. Available from URL: http://www.ema.europa.eu [Accessed 2011 Mar 21].
245. Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-53.
246. Mousa SA. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban. Methods Mol Biol 2010; 663: 181-201.
247. Wong PC, Crain EJ Jr, Nguan O, Watson CA, Racanelli A. Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. Thromb Res 1996; 83: 117-26. (Pubitemid 26274429)
248. Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 2011; 31: 478-92.
249. Quan ML, Pruitt JR, Ellis CD, et al. Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors. Bioorg Med Chem Lett 1997; 7: 2813-8. (Pubitemid 27472834)
250. Quan ML, Liauw AY, Ellis CD, et al. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors 1. J Med Chem 1999; 42: 2752-59. (Pubitemid 29370421)
251. Pruitt JR, Pinto DJ, Estrella MJ, et al. Isoxazolines and isoxazoles as factor Xa inhibitors. Bioorg Med Chem Lett 2000; 10: 685-9. (Pubitemid 30215863)
252. Fevig JM, Pinto DJ, Han Q, et al. Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core. Bioorg Med Chem Lett 2001; 11: 641-5. (Pubitemid 32187946)
253. Pinto DJ, Orwat MJ, Wang S, et al. Discovery of 1- [3- aminomethyl)phenyl]-N- [3-fluoro-2'-(methylsulfonyl)- [1,1'- biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of coagulation factor Xa. J Med Chem 2001; 44: 566-78. (Pubitemid 32156098)
254. Quan ML, Lam PY, Han Q, et al. Discovery of 1-(3'- aminobenzisoxazol-5'- yl)-3-trifluoromethyl-N- [2-fluoro-4-[(2'- dimethylaminomethyl)imidazol-1-yl] phenyl]-1H-pyrazole-5- carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 2005; 48: 1729-44. (Pubitemid 40396307)
255. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery on behalf of the razaxaban investigators. Blood 2003; 102: Abstract 41.
256. Weitz JI, Hirsh J, Samama MM; American College of Chest Physicians. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 234S-256S. (Pubitemid 351892968)
257. Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4- methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7- tetrahydro-1H-pyrazolo [3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007; 50: 5339-56. (Pubitemid 350057846)
258. Eliquis® (apixaban) summary of product characteristics. Available from URL: http://www.ema.europa.eu [Accessed 2011 Jul 14].
259. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-15.
260. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-98.
261. Zikria J, Ansell J. Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin? Discov Med 2009; 8: 196-203.
262. Kohrt JT, Bigge CF, Bryant JW, et al. The discovery of (2R,4R)-N- (4-chlorophenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4- methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor. Chem Biol Drug Des 2007; 70: 100-12. (Pubitemid 47228656)
263. Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008; 6: 1542-9.
264. Zhang P, Huang W, Wang L, et al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,Ndimethylcarbamimidoyl) benzamido)-5- methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett 2009; 19: 2179-85.
265. Rupin A, Marx I, Vallez MO, Mennecier P, Gloanec P, de Nanteuil G, et al. S35972, a direct acting thrombin inhibitor with a high oral bioavailability and antithrombotic efficacy. J Thromb Haemost 2011; 9: 1375-82.
266. Viskov C, Just M, Laux V, Mourier P, Lorenz M. Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost 2009; 7: 1143-51.
267. Kishimoto TK, Qi YW, Long A, et al. M118-a rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes. Thromb Haemost 2009; 102: 900-6.
268. Guertin KR, Choi YM. The discovery of the factor Xa inhibitor otamixaban: from lead identification to clinical development. Curr Med Chem 2007; 14: 2471-81. (Pubitemid 47618035)
269. Chu V, Brown K, Colussi D, et al. Pharmacological characterization of a novel factor Xa inhibitor, FXV673. Thromb Res 2001; 103: 309-24. (Pubitemid 32787022)
270. Qian X, Zheng B, Burke B, Saindane MT, Kronenthal DR. A stereoselective synthesis of BMS-262084, an azetidinone-based tryptase inhibitor. J Org Chem 2002; 67: 3595-600. (Pubitemid 34563968)
271. Zhang H, Löwenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010; 116: 4684-92.
272. Buchanan MS, Carroll AR, Wessling D, et al. Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa. J Med Chem 2008; 51: 3583-7. (Pubitemid 351875013)
273. Verhamme P, Pakola S, Jensen TJ, et al. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther 2010; 32: 1205-20.
274. Graefe-Mody EU, Schühly U, Rathgen K, Stähle H, Leitner JM, Jilma B. Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. J Thromb Haemost 2006; 4: 1502-9.
275. Bianchini EP, Fazavana J, Picard V, Borgel D. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives. Blood 2011; 117: 2054-60.
276. Lu G, Luan P, Hollenbach SJ, et al. Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors. J Thromb Haemost 2009; 7(Suppl.2): OC-TH-107.
277. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics 2010. Nat Rev Drug Discov 2010; 9: 537-50.
278. Dyke CK, Steinhubl SR, Kleiman NS, et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drugantidote pair for the controlled regulation of factor IXa activity. Circulation 2006; 114: 2490-7. (Pubitemid 44901522)
279. Becker RC, Chan MY. REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis. Curr Opin Mol Ther 2009; 11: 707-15.
280. Andricopulo AD, Salum LB, Abraham DJ. Structure-based drug design strategies in medicinal chemistry. Curr Top Med Chem 2009; 9: 771-90.
281. Maignan S, Mikol V. The use of 3D structural data in the design of specific factor Xa inhibitors. Curr Top Med Chem 2001; 1: 161-74.
282. Leadley RJ Jr, Chi L, Rebello SS, Gagnon A. Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents. J Pharmacol Toxicol Methods 2000; 43: 101-16. (Pubitemid 32057032)
283. Atay J, Fiumara K, Piazza G, Fanikos J, Goldhaber SZ. Cost analysis of substituting dabigatran for warfarin in an anticoagulation management service. J Am Coll Cardiol 2011; 57: 1188.
284. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1-11